CDKL5

Gene

The CDKL5 gene is located on the X chromosome at locus Xp22. It undergoes alternative splicing to produce multiple transcript variants. Pathogenic variants in CDKL5 can result in either loss of function or altered subcellular localization of the protein, which contributes to disease pathology. The gene is expressed predominantly in the brain and is particularly active during early developmental stages.

Structure

CDKL5 encodes a serine/threonine kinase with a highly conserved catalytic domain similar to cyclin-dependent kinases (CDKs), though it functions independently of cyclins. The C-terminal region of the protein plays a critical role in its subcellular localization and regulation. During neuronal development, CDKL5 localizes to both the nucleus and cytoplasm, with nuclear localization being essential for its role in gene regulation and splicing.

Function

CDKL5 plays a central role in neuronal function by regulating signal transduction pathways that influence dendritic spine morphology, synaptogenesis, and neuronal survival. It is involved in the phosphorylation of target proteins that modulate neuronal activity and gene expression. CDKL5 has also been shown to interact with nuclear speckles and influence RNA splicing machinery, which may underlie some of its neurodevelopmental functions.

Clinical significance

Mutations in CDKL5 cause CDKL5 deficiency disorder (CDD), an X-linked dominant condition characterized by early-onset epileptic seizures, severe intellectual disability, and motor dysfunction. CDD is considered distinct from classic Rett syndrome, although overlapping features have been noted, especially in female patients. Clinical presentations of CDKL5 mutations can vary widely, and cases have been reported in both males and females. Genetic testing for CDKL5 is recommended in infants presenting with epileptic encephalopathy of unknown origin. Research is ongoing into potential therapies, including gene therapy and molecular modulation of downstream targets.

References

References

1. (October 1997). "Serological crossreactivity between Brucella abortus and Yersinia enterocolitica 0:9. III. Specificity of the in vitro antigen-specific gamma interferon test for bovine brucellosis diagnosis in experimentally Yersinia enterocolitica 0:9-infected cattle". Veterinary Microbiology.
2. (April 2010). "Xp22.3 genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy". Epilepsia.
3. (August 2019). "Splicing Mutations Impairing CDKL5 Expression and Activity Can be Efficiently Rescued by U1snRNA-Based Therapy". International Journal of Molecular Sciences.
4. (August 2018). "Damage and Failure of Axonal Microtubule under Extreme High Strain Rate: An In-Silico Molecular Dynamics Study". Scientific Reports.
5. (October 2013). "Clinical and microbiological characteristics of Bartholin gland abscesses". Obstetrics and Gynecology.
6. (October 1996). "Fetal endoscopic tracheal occlusion ('Fetendo-PLUG') for congenital diaphragmatic hernia". Journal of Pediatric Surgery.
7. (January 2017). "Subcellular distribution of cyclin-dependent kinase-like 5 (CDKL5) is regulated through phosphorylation by dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A)". Biochemical and Biophysical Research Communications.
8. (October 2008). "CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail". The Journal of Biological Chemistry.
9. (November 2023). "CDKL5-mediated developmental tuning of neuronal excitability and concomitant regulation of transcriptome". Human Molecular Genetics.
10. (June 2023). "Early-onset brain alterations during postnatal development in a mouse model of CDKL5 deficiency disorder". Neurobiology of Disease.
11. (December 2009). "CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery". Human Molecular Genetics.
12. (May 1989). "99Tcm-labelled anti-CEA monoclonal antibody for tumour immunoscintigraphy: first clinical results". Nuclear Medicine Communications.
13. (August 2024). "Novel CDKL5 targets identified in human iPSC-derived neurons". Cellular and Molecular Life Sciences.
14. (July 1994). "Deficient ileal 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in sitosterolemia: sitosterol is not a feedback inhibitor of intestinal cholesterol biosynthesis". Metabolism.
15. (June 2018). "Overseas doctors must not be used just to fill rota gaps, says leading consultant". BMJ.
16. (November 1979). "Effects of ring substitution on the pre- and postjunctional alpha-adrenergic activity of aryliminoimidazolidines". Naunyn-Schmiedeberg's Archives of Pharmacology.
17. (October 2019). "Rett Syndrome and CDKL5 Deficiency Disorder: From Bench to Clinic". International Journal of Molecular Sciences.
18. "CDKL5 Deficiency Disorder - Symptoms, Causes, Treatment". NORD.
19. (October 2024). "Preclinical studies of gene replacement therapy for CDKL5 deficiency disorder". Molecular Therapy.
20. (May 2022). "Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial". The Lancet. Neurology.
21. (2 October 2024). "Genetic Testing for CDKL5 Deficiency Disorder". Marinus Pharmaceuticals.
22. (October 2022). "Expression of a Secretable, Cell-Penetrating CDKL5 Protein Enhances the Efficacy of Gene Therapy for CDKL5 Deficiency Disorder". Neurotherapeutics.